Startups
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.
Casma Therapeutics closed on a Series A round totaling $58.5 million. The company was solely funded by Third Rock Ventures.
Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
Ironwood Pharmaceuticals will split into two independent companies, Ironwood and what is currently being dubbed R&D Co.
Proniras Corporation launched from Accelerator Life Science Partners to treat nerve agents. The company recently received a contract from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) for $89.5 million.
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.
Cedilla Therapeutics, headquartered in Cambridge, Massachusetts, launched with a $56.2 million Series A round from Third Rock Ventures.
Urovant Sciences has been busy the past few weeks. In March the company initiated a Phase III trial for an overactive bladder treatment, strengthened its management team and established a U.S. headquarters in Irvine, California.
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash.
PRESS RELEASES